| Literature DB >> 26564313 |
Kirsty Ross1,2, Emma Pailler1,2, Vincent Faugeroux1,2, Melissa Taylor1, Marianne Oulhen1,2, Nathalie Auger3, David Planchard4, Jean-Charles Soria1,4, Colin R Lindsay1,2, Benjamin Besse4, Philippe Vielh1,2,3, Françoise Farace1,2.
Abstract
In non-small-cell lung cancer (NSCLC), genotyping tumor biopsies for targetable somatic alterations has become routine practice. However, serial biopsies have limitations: they may be technically difficult or impossible and could incur serious risks to patients. Circulating tumor cells (CTCs) offer an alternative source for tumor analysis that is easily accessible and presents the potential to identify predictive biomarkers to tailor therapies on a personalized basis. Examined here is our current knowledge of CTC detection and characterization in NSCLC and their potential role in EGFR-mutant, ALK-rearranged and ROS1-rearranged patients. This is followed by discussion of the ongoing issues such as the question of CTC partnership as diagnostic tools in NSCLC.Entities:
Keywords: ALK rearrangement; Circulating tumor cells; EGFR mutation; diagnostic biomarkers; non-small-cell lung carcinoma
Mesh：
Substances：
Year: 2015 PMID： 26564313 DOI： 10.1586/14737159.2015.1111139
Source DB: PubMed Journal: Expert Rev Mol Diagn ISSN： 1473-7159 Impact factor: 5.225